Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma

Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone Medical Center, New York, NY, presents the encouraging results of the LINKER-MM1 trial (NCT03761108), which assessed the safety and efficacy of linvoseltamab (linvo), a novel B-cell maturation antigen (BCMA)-targeting T-cell engaging bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial enrolled a diverse group of patients, most with triple-class refractory disease. Intravenous infusion of linvo resulted in a significant improvement in progression-free survival (PFS) and a response rate of around 70%. The safety profile was manageable, with low-grade cytokine release syndrome (CRS) occurring in a predictable pattern, allowing patients to be moved to the outpatient setting. As the frequency of infusions was decreased from weekly to monthly by the end of the trial, the infection rate observed in patients markedly dropped. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.